If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Two additional amino acids are in some species coded for by codons that are usually interpreted as stop codons: In addition to the specific amino acid codes, placeholders are used in cases where chemical or crystallographic analysis of a peptide or protein cannot conclusively determine the identity of a residue. They are also used to summarize conserved protein sequence motifs. The use of single letters to indicate sets of similar residues is similar to the use of abbreviation codes for degenerate bases.
In 2007, Waters served as co-chair for the International Symposium on Dynamic Combinatorial Chemistry (November). The year after that, she was an advisory board member of International Symposia on Macrocyclic and Supramolecular Chemistry (ISMSC). In 2009, she was a guest editor for the December issue of Current Opinion in Chemical Biology. From 2009 to 2015, she was an advisory board member of International Symposia on Macrocyclic and Supramolecular Chemistry (ISMSC). In 2011, Waters was a co-organizer of the Mesilla Chemistry Workshop on "Aromatic Interactions in Chemistry and Biology"(with Ken Houk, UCLA Dept of Chemistry). In 2012, Waters was a section editor for "Supramolecular Chemistry: From Molecules to Nanomaterials" (John Wiley and Sons). In 2013, she was the co-chair, of American Peptide Society Meeting (with David Lawrence, UNC Dept of Chemistry) and a guest editor for Accounts of Chemical Research for the "Aromatic Interactions in Chemistry and Biology" article in the April issue. From 2014 to 2020, Waters was an editorial advisory board member of the Journal of the American Chemical Society.
It is believed that the tyrosine amino acid found along the amino acid sequence of alpha-sarcin allows for the specificity when alpha-sarcin binds to the rRNA. It is the alcohol group found on the tyrosine amino acid that allows for this binding. This was determined in tests that removed the alcohol group, replacing tyrosine with phenylalanine, and the binding affinity was greatly reduced. The region of the DNA that makes alpha-sarcin is highly conserved, along with the corresponding sequence on the targeted ribosome. The corresponding sequence on the targeted ribosome is a centered around a guanine nucleotide located on what is called the "bulged-G motif".
Sources: en.wikipedia.org
The name Ghana comes from Wagadu, an empire in west Africa from the 3rd to 12th centuries; Wagadu was termed Ghana by Arab traders involved in the trans-Saharan trade. Ghana is thought to originate from the title Kaya Maghan of the rulers of Wagadu, which translates as ruler of gold.
When causing the same disease, clinical demonstrations of E. floccosum are generally indistinguishable from other dermatophytes, except for tinea pedis: infections involving E. floccosum can demonstrate marked scaling in patient's toe and sole and produce punctate lesions nearby. Brownish macules could derive from some of these lesions. Traditionally, diseases are diagnosed with physical and Wood's lamp examinations. Unlike some Microsporium species, Epidermophyton, as well as Trichophyton do not fluoresce under the ultraviolet light of a Wood's lamp. Fungal cultures further distinguish Epidermophyton from other dermatophytes based on the absence of microconidia. Molecular advances have decreased the time of identification from 3–4 weeks to 3–4 days. Samples obtained from patient nail, hair, and skin scale can undergo PCR-RFLP, which distinguishes between 12 dermatophyte species based on their individual restriction enzyme profiles, including one for E. floccosum. A real time PCR protocol is also available for the specific detection of E. floccosum, allowing identification as fast as four hours after sample lysis.
== Trade names == Common trade names include Centrac, Centrax, Demetrin, Lysanxia, Mono Demetrin, Pozapam, Prasepine, Prazene, Reapam and Trepidan. Trade names vary depending on the country; Austria: Demetrin, Belgium: Lysanxia, France: Lysanxia, Germany: Demetrin; Mono Demetrin, Greece: Centrac, Ireland: Centrax, Italy: Prazene; Trepidan, Macedonia: Demetrin, Prazepam, Netherlands: Reapam, Portugal: Demetrin, South Africa: Demetrin, Switzerland: Demetrin, Thailand: Pozapam; Prasepine.
Sources: en.wikipedia.org
The GIUK gap (sometimes written G-I-UK) is an area in the northern Atlantic Ocean that forms a naval choke point. Its name is an initialism for Greenland, Iceland, and the United Kingdom, the gap being the two stretches of open ocean among these three landmasses. It separates the Norwegian Sea and the North Sea from the open Atlantic Ocean. The term is typically used in relation to military topics. The area has been considered strategically important since the beginning of the 20th century.
== Venom == The venom of the Wagler's pit viper contains four novel peptides (Waglerins 1-4). The Waglerins produce fatal respiratory paralysis of adult mice. An initial study indicated that micromolar concentrations of Waglerin 1 act both pre- and postsynaptically to inhibit transmission across rat neuromuscular junctions. However, Waglerin-1 is a more potent inhibitor of transmission across the mouse neuromuscular junction. A subsequent study demonstrated that Waglerin-1 inhibited the adult mouse endplate response to acetylcholine with an IC50 of 50 nanomolar. In striking contrast, transmission across neuromuscular junctions of neonatal or transgenic mice lacking the adult acetylcholine receptor was not altered by micromolar concentrations of Waglerin-1. Biochemical studies demonstrated that the exquisite selectivity of Waglerin-1 for the adult mouse acetylcholine receptor relies upon several amino acid residues unique to the epsilon subunit of the adult mouse acetylcholine receptor. Waglerin-1's selectivity for the epsilon-subunit containing acetylcholine receptor of adult mice is complemented by selectivity of small peptide toxins purified from the venom of Conus geographus and Conus pergrandis for the gamma-subunit containing acetylcholine receptor of neonatal skeletal muscle. The Waglerins and complementary conotoxins are useful tools to discover the contribution of acetylcholine receptor subunits to synaptogenesis. In addition, study of the Waglerins and related toxic peptides may lead to the discovery of novel molecular targets for drug development.
== Atomic number == Before 1913, chemists adhered to Mendeleev's principle that chemical properties derived from atomic weight. However, several places in the periodic table were inconsistent with this concept. For example cobalt and nickel seemed reversed. There were also attempts to understand the relationship between the atomic mass and nuclear charge. Rutherford knew from experiments in his lab that helium must have a nuclear charge of 2 and a mass of 4; this 1:2 ratio was expected to hold for all elements. In 1913 Antonius van den Broek hypothesized that the periodic table should be organized by charge, denoted by Z, not atomic mass and that Z was not exactly half of the atomic weight for elements. This solved the cobalt-nickel issue. Placing cobalt (Z=27, mass of 58.97), before the heavier nickel (Z=28, mass of 58.68) gave the ordering expected by chemical behavior. In 1913–1914 Moseley tested Broek's hypothesis experimentally by using X-ray spectroscopy. He found that the most intense short-wavelength line in the X-ray spectrum of a particular element, known as the K-alpha line, was related to the element's charge its atomic number, Z. Moseley found that the frequencies of the radiation were related in a simple way to the atomic number of the elements for a large number of elements.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.